Compare Church & Dwight Co., Inc. (CHD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Summit Therapeutics Inc — how do they compare? Church & Dwight Co., Inc. trades at $97.3 (market cap $22.61B), while Summit Therapeutics Inc trades at $15.07 (market cap $12.01B). The key difference: Church & Dwight Co., Inc. is the larger of the two by market cap, and Church & Dwight Co., Inc. pays a 1.29% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CHD | SMMT | |
|---|---|---|
Market Cap | $22.61B | $12.01B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $29.32 |
52-Week Low | $81.60 | $13.05 |
Enterprise Value | $24.31B | $11.43B |
Dividend Yield | 1.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $97.16, up 0.83% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with 11.81% net margins and consistent organic growth, supported by strategic acquisitions like Miss Mouth's brand. Analyst consensus remains positive with a $105.60 price target, though cash flow trends show recent negative net flows.
CHD presents a balanced opportunity with solid brand execution and margin expansion potential, offset by cash flow volatility and competitive pressures. The stock's premium valuation requires sustained earnings growth to justify upside, with Q2 2026 earnings on July 31 as a key catalyst.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
